Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2021-05-13 Purchase | 2021-05-17 07:02 am | Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director | 5,925,925 | $1.35 | $7,999,999 | 7,804,778 (Indirect) | View |
| 2020-11-17 Purchase | 2020-11-19 4:40 pm | Keros Therapeutics Inc. | KROS | Nussbaum Ran Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. Director 10% Owner | 60,000 | $50 | $3,000,000 | 155,262 (Indirect) | View |
| 2020-04-13 Purchase | 2020-04-13 5:16 pm | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 437,499 | $16 | $6,999,984 | 149,262 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-05-30 Option Award | 2024-06-03 4:15 pm | N/A 2034-05-29 | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 10,000 | $0 | 10,000 (Direct) | View |
| 2023-06-06 Option Award | 2023-06-08 4:44 pm | N/A 2033-06-05 | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 10,000 | $0 | 10,000 (Direct) | View |
| 2022-06-06 Exercise(A) | 2023-02-28 12:29 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 1,030 | $5 | 1,434,958 (Indirect) | View |
| 2022-06-06 Exercise(A) | 2023-02-28 12:29 pm | 2015-09-01 2022-09-01 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 1,030 | $0 | 1,434,958 (Indirect) | View |
| 2022-10-21 Exercise(A) | 2023-02-28 12:23 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 47,999 | $5.94 | 1,485,168 (Indirect) | View |
| 2022-10-21 Exercise(A) | 2023-02-28 12:23 pm | 2018-12-27 2022-12-27 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 47,999 | $0 | 1,485,168 (Indirect) | View |
| 2022-06-16 Exercise | 2023-02-28 12:21 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 2,211 | $5 | 1,437,169 (Indirect) | View |
| 2022-06-16 Exercise | 2023-02-28 12:21 pm | 2015-09-01 2022-09-01 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 2,211 | $0 | 1,437,169 (Indirect) | View |
| 2022-11-29 Exercise | 2022-11-30 4:40 pm | N/A 2023-10-07 | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 7,176 | $0 | 1,226,412 (Indirect) | View |
| 2022-11-29 Exercise | 2022-11-30 4:40 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 7,176 | $0.0001 | 1,226,412 (Indirect) | View |
Ownership(A) | 2022-11-30 4:36 pm | N/A 2023-10-07 | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 0 | $0 | 7,176 (Indirect) | View |
| 2022-10-21 Exercise | 2022-10-25 4:57 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 47,999 | $5.94 | 1,481,927 (Indirect) | View |
| 2022-10-21 Exercise | 2022-10-25 4:57 pm | 2018-12-27 2022-12-27 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 47,999 | $0 | 1,481,927 (Indirect) | View |
| 2022-06-06 Exercise | 2022-08-25 3:25 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 1,030 | $5 | 1,433,928 (Indirect) | View |
| 2022-06-06 Exercise | 2022-08-25 3:25 pm | 2015-09-01 2022-08-31 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 1,030 | $0 | 1,433,928 (Indirect) | View |
| 2022-06-15 Option Award | 2022-06-17 08:26 am | N/A 2032-06-15 | Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2022-06-08 Option Award | 2022-06-10 3:36 pm | N/A 2032-06-08 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 10,000 | $0 | 10,000 (Indirect) | View |
| 2022-06-01 Option Award | 2022-06-03 4:30 pm | N/A 2032-05-31 | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 8,293 | $0 | 8,293 (Direct) | View |
| 2021-03-25 Exercise(A) | 2021-06-09 1:46 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 1,030 | $5 | 1,431,717 (Indirect) | View |
| 2021-03-25 Exercise(A) | 2021-06-09 1:46 pm | 2014-07-27 2021-07-27 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 1,030 | $0 | 1,431,717 (Indirect) | View |
| 2021-06-07 Option Award | 2021-06-09 1:42 pm | N/A 2031-06-06 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 10,000 | $0 | 1,443,928 (Indirect) | View |
| 2021-03-25 Exercise | 2021-06-09 1:42 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 2,211 | $5 | 1,443,928 (Indirect) | View |
| 2021-03-25 Exercise | 2021-06-09 1:42 pm | 2014-07-27 2021-07-27 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 2,211 | $0 | 1,443,928 (Indirect) | View |
| 2021-06-01 Option Award | 2021-06-03 5:34 pm | N/A 2031-05-31 | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 8,293 | $0 | 8,293 (Direct) | View |
| 2021-05-19 Option Award | 2021-05-20 4:10 pm | N/A 2031-05-19 | Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2021-03-24 Exercise | 2021-04-22 5:18 pm | N/A N/A | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 1,030 | $5 | 1,465,199 (Indirect) | View |
| 2021-03-24 Exercise | 2021-04-22 5:18 pm | 2014-07-27 2021-07-27 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 1,030 | $0 | 1,465,199 (Indirect) | View |
| 2021-01-22 Equity Swap | 2021-01-26 5:07 pm | N/A N/A | Prevail Therapeutics Inc. | PRVL | Nussbaum Ran Director | 1,576,881 | $0 | 0 (Indirect) | View |
| 2021-01-22 Disposition | 2021-01-26 5:07 pm | N/A N/A | Prevail Therapeutics Inc. | PRVL | Nussbaum Ran Director | 17,000 | $0 | 0 (Direct) | View |
| 2020-06-17 Option Award | 2020-06-19 6:38 pm | N/A 2030-06-17 | Prevail Therapeutics Inc. | PRVL | Nussbaum Ran Director | 17,000 | $0 | 17,000 (Direct) | View |
| 2020-06-08 Option Award | 2020-06-10 6:41 pm | N/A 2030-06-07 | UroGen Pharma Ltd. | URGN | Nussbaum Ran Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2020-05-20 Option Award | 2020-05-22 4:10 pm | N/A 2030-05-20 | Eloxx Pharmaceuticals Inc. | ELOX | Nussbaum Ran Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 3,545,100 | $0 | 149,262 (Indirect) | View |
Ownership | 2020-04-07 7:34 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 0 | $0 | 4,297,008 (Indirect) | View |
| 2020-01-16 Disposition | 2020-01-16 3:57 pm | N/A 2027-11-08 | ARQULE INC | ARQL | Nussbaum Ran Director | 90,000 | $0 | 0 (Direct) | View |
| 2020-01-16 Equity Swap | 2020-01-16 3:57 pm | N/A N/A | ARQULE INC | ARQL | Nussbaum Ran Director | 8,744,820 | $20 | 0 (Indirect) | View |
| 2019-12-24 Tax Withholding | 2019-12-27 8:48 pm | N/A N/A | ARQULE INC | ARQL | Nussbaum Ran Director | 145,301 | $20.11 | 2,134,350 (Indirect) | View |
| 2019-12-24 Exercise | 2019-12-27 8:48 pm | N/A 2022-05-08 | ARQULE INC | ARQL | Nussbaum Ran Director | 1,669,714 | $0 | 2,134,350 (Indirect) | View |
| 2019-12-24 Exercise | 2019-12-27 8:48 pm | N/A N/A | ARQULE INC | ARQL | Nussbaum Ran Director | 1,669,714 | $1.75 | 2,134,350 (Indirect) | View |